Zentalis Pharmaceuticals Inc reports results for the quarter ended in March - Earnings Summary

Zentalis Pharmaceuticals

10/05/2023 13:00

* Zentalis Pharmaceuticals Inc  ZNTL.OQ  reported a
quarterly
adjusted loss of $1.07​​ per share for the quarter ended in
March. The mean expectation of nine analysts for the quarter was
for a loss of $1.02 per share.
    * Reported revenue was zero​; analysts expected zero. 
    * Zentalis Pharmaceuticals Inc's reported EPS for the
quarter was
a loss of $1.07​.
    * The mean earnings estimate of analysts had risen by
about 0.1%
in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company. 
    * Zentalis Pharmaceuticals Inc shares had risen by 32.6%
this
quarter and gained 13.3% so far this year.
    * The company reported a quarterly loss of $63.22 million.
    * Wall Street's median 12-month price target for Zentalis
Pharmaceuticals Inc is $48.00 
    * The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 11 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell." 

This summary was machine generated from LSEG Refinitiv data May
10 at 12:00 p.m. UTC. ​All figures in US dollars unless
otherwise stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Mar. 31 2023      -1.02          -1.07          Missed
 Dec. 31 2022      -1.06          -0.92          Beat
 Sep. 30 2022      -1.17          -0.96          Beat
 Jun. 30 2022      -1.19          -1.34          Missed